President and Chief Executive Officer
United States of America
Paula Soteropoulos is a global strategic and operating management executive with nearly 30 years of experience and success building high-performance global teams, leading complex development programs from early stage through approval, and commercializing global products. Ms. Soteropoulos joined Akcea as President and Chief Executive Officer upon its formation in January 2015. Prior to joining Akcea, Ms. Soteropoulos was a member of the executive leadership team of Moderna Therapeutics as the Cardiometabolic Business Unit General Manager and Senior Vice President of Strategic Alliances. Prior to Moderna, she spent 21 years at Genzyme Corporation where she was instrumental in advancing new products from discovery through clinical development and commercialization, with significant roles driving strategy, sales and marketing, and business development. Additionally, she led manufacturing process development, strategic capacity planning, and supply chain development. Prior to Genzyme, Ms. Soteropoulos was a bioprocess engineering consultant for various biopharmaceutical companies. She serves on the Board of Directors of uniQure B.V. and on the Advisory Board of the Tufts University Chemical and Biological Engineering Department. Ms. Soteropoulos earned her B.S. and Master’s degrees in Chemical and Biochemical Engineering from Tufts University and earned an executive management certificate from Darden School of Business, University of Virginia. She is also a past honoree of Mass High Tech’s Women to Watch.
Therapies focused on lipid disorders and cardiometabolic diseases, critically needed therapies